Please try another search
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Hak-Woo Kim | - | 2016 | Non-Executive Director |
Yoon-Ho Kook | - | 2016 | Non-Executive Director |
Eun-Sang Moon | - | 2014 | Chairman & CEO |
Hyoung-Kyu Kim | - | 2016 | Non-Executive Director |
Chul Park | - | 2015 | Non-Executive Director |
Sung-Jin Yoon | - | 2015 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review